Literature DB >> 8250970

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.

P J Worland1, G Kaur, M Stetler-Stevenson, S Sebers, O Sartor, E A Sausville.   

Abstract

The flavone L86-8275 [(-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-[4-(3-hydroxy-1-methyl)- piperidinyl]-4H-1-benzopyran-4-one] delayed the progression of aphidicolin-synchronized MDA-468 breast carcinoma cells through S phase and prevented progression through G2. L86-8275 prevented the G2-related increase in histone H1 kinase activity mediated by cyclin-dependent kinase-1 (p34cdc2 kinase). L86-8275 inhibited [32P]orthophosphate labeling of p34cdc2 threonine and tyrosine residues and decreased the phosphotyrosine content of p34cdc2. Diminution of p34cdc2 phosphotyrosine appeared selective, as a general depletion of cellular phosphotyrosine was not observed. The mass of p34cdc2 in L86-8275-exposed cells was not decreased during the period over which these effects occurred. [35S]Methionine labeling of p34cdc2 or other cellular proteins was not inhibited at concentrations that were effective for complete cellular growth inhibition. We hypothesize that L86-8275 interferes with the normal cell cycle-dependent phosphorylation of p34cdc2, resulting in decreased kinase activity and cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250970     DOI: 10.1016/0006-2952(93)90590-s

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 2.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Authors:  A M Senderowicz
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:  Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells.

Authors:  Suzy Kim; Hong-Gyun Wu; Jin Hee Shin; Hye Jin Park; In Ah Kim; Il Han Kim
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

6.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

7.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:  Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

8.  Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.

Authors:  Wenjun Ni; Jia Ji; Zunyan Dai; Audrey Papp; Amy J Johnson; Sunjoo Ahn; Katherine L Farley; Thomas S Lin; James T Dalton; Xiaobai Li; David Jarjoura; John C Byrd; Wolfgang Sadee; Michael R Grever; Mitch A Phelps
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

9.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

Authors:  V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

10.  Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.

Authors:  Mitch A Phelps; Darlene M Rozewski; Jeffrey S Johnston; Katherine L Farley; Katie A Albanese; John C Byrd; Thomas S Lin; Michael R Grever; James T Dalton
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-04-22       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.